Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Lifevantage Corporation (LFVN : NSDQ)

• Company Description    Lifevantage Corporation is a health and nutrition company. The company is the maker of Protandim(R), the Nrf2 Synergizer(R) patented dietary supplement, the TrueScience(TM) Anti-Aging Skin Care Regimen, Canine Health and the AXIO(TM) energy product line. Lifevantage Corporation is headquartered in Salt Lake City, Utah. Number of Employees: 223

• Price / Volume Information    Yesterday's Closing Price: $6.25 Daily Weekly Monthly 20 Day Moving Average: 49,850 shares Shares Outstanding: 12.53 (millions) Market Capitalization: $78.30 (millions) Beta: 0.73 52 Week High: $12.10 52 Week Low: $3.90 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.44% -6.02% 12 Week -5.45% -7.46% Year To Date 1.46% -10.02%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3300 N. Triumph Blvd Suite 700 - LEHI,UT 84043 USA ph: 801-432-9000 fax: 801-880-0699 reed.anderson@icrinc.com http://www.lifevantage.com

• General Corporate Information    Officers Terrence Moorehead - Chief Executive Officer and President Raymond B. Greer - Chairman Carl A. Aure - Chief Financial Officer Rajendran Anbalagan - Director Michael A. Beindorff - Director Peer Information Lifevantage Corporation (ITRJ) Lifevantage Corporation (BRLI.) Lifevantage Corporation (GOGY) Lifevantage Corporation (PSTX.) Lifevantage Corporation (ELGXQ) Lifevantage Corporation (CAH) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED/DENTAL-SUPP Sector: Medical CUSIP: 53222K205 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/03/26 Share - Related Items Shares Outstanding: 12.53 Most Recent Split Date: 10.00 (0.14:1) Beta: 0.73 Market Capitalization: $78.30 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 3.20% Current Fiscal Quarter EPS Consensus Estimate: $0.03 Indicated Annual Dividend: $0.20 Current Fiscal Year EPS Consensus Estimate: $0.39 Payout Ratio: 0.36 Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: 09/01/2026 - $0.05 Next EPS Report Date: 11/03/26

• Fundamental Ratios P/E Current FY Estimate: 16.03 Trailing 12 Months: 11.16 PEG Ratio: - Price Ratios Price/Book: 2.35 Price/Cash Flow: 7.90 Price / Sales: 0.43 EPS Growth vs. Year Ago Period: -35.29% vs. Previous Quarter: -8.33% Sales Growth vs. Year Ago Period: -23.11% vs. Previous Quarter: -3.06% ROE 06/30/26 - 21.56 03/31/26 - 23.89 12/31/25 - 29.59 ROA 06/30/26 - 11.62 03/31/26 - 12.47 12/31/25 - 14.67 Current Ratio 06/30/26 - 1.89 03/31/26 - 1.96 12/31/25 - 2.03 Quick Ratio 06/30/26 - 1.09 03/31/26 - 1.04 12/31/25 - 1.03 Operating Margin 06/30/26 - 3.93 03/31/26 - 4.10 12/31/25 - 4.75 Net Margin 06/30/26 - 2.78 03/31/26 - 2.94 12/31/25 - 3.74 Pre-Tax Margin 06/30/26 - 3.32 03/31/26 - 3.46 12/31/25 - 4.42 Book Value 06/30/26 - 2.66 03/31/26 - 2.60 12/31/25 - 2.60 Inventory Turnover 06/30/26 - 2.21 03/31/26 - 2.17 12/31/25 - 2.17 Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©